Is It Possible to Develop a "Universal" Influenza Virus Vaccine? Potential for a Universal Influenza Vaccine

Overview

Journal Cold Spring Harb Perspect Biol

Specialties Biology
Molecular Biology

Date 2017 Jul 1

PMID 28663208

Citations 16

Authors

James E Crowe Jr

Affiliations

Soon will be listed here.

Abstract

Development of optimal vaccines for influenza is challenging, in part as a result of the high antigenic variability in field strains associated with genetic shift from reassortment and genetic drift from point mutations. Discovery of conserved antigenic sites on the hemagglutinin (HA) protein for neutralizing antibodies suggested the possibility that influenza vaccines could be developed that induce focused antibody responses to the conserved neutralizing determinants, especially the HA stem region. Recent studies have focused on the antigenicity and immunogenicity of such domains, using monoclonal antibodies and candidate-engineered HA stem-based vaccines. Much progress has been made, but we still do not fully understand the biology of the immune response to this unique antigenic region.

Citing Articles

Dual neutralization of influenza virus hemagglutinin and neuraminidase by a bispecific antibody leads to improved antiviral activity.

Moirangthem R, Cordela S, Khateeb D, Shor B, Kosik I, Schneidman-Duhovny D Mol Ther. 2024; 32(10):3712-3728.

PMID: 39086132 PMC: 11489563. DOI: 10.1016/j.ymthe.2024.07.023.

Quantitatively Visualizing Bipartite Datasets.

Einav T, Khoo Y, Singer A Phys Rev X. 2024; 13(2).

PMID: 38831998 PMC: 11146982. DOI: 10.1103/physrevx.13.021002.

Differential recognition of influenza A virus H1N1 neuraminidase by DNA vaccine-induced antibodies in pigs and ferrets.

Linnea Tingstedt J, Stephen C, Risinger C, Blixt O, Gunalan V, Johansen I Front Immunol. 2023; 14:1200718.

PMID: 37313410 PMC: 10258320. DOI: 10.3389/fimmu.2023.1200718.

An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults.

Widge A, Hofstetter A, Houser K, Awan S, Chen G, Burgos Florez M Sci Transl Med. 2023; 15(692):eade4790.

PMID: 37075129 PMC: 10619166. DOI: 10.1126/scitranslmed.ade4790.

Magnitude and breadth of antibody cross-reactivity induced by recombinant influenza hemagglutinin trimer vaccine is enhanced by combination adjuvants.

Hernandez-Davies J, Dollinger E, Pone E, Felgner J, Liang L, Strohmeier S Sci Rep. 2022; 12(1):9198.

PMID: 35654904 PMC: 9163070. DOI: 10.1038/s41598-022-12727-y.

References

Corti D, Voss J, Gamblin S, Codoni G, Macagno A, Jarrossay D . A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011; 333(6044):850-6. DOI: 10.1126/science.1205669. View

Janjua N, Skowronski D, Hottes T, Osei W, Adams E, Petric M . Seasonal influenza vaccine and increased risk of pandemic A/H1N1‐related illness: first detection of the association in British Columbia, Canada. Clin Infect Dis. 2010; 51(9):1017-27. PMC: 7107856. DOI: 10.1086/656586. View

Monsalvo A, Batalle J, Lopez M, Krause J, Klemenc J, Hernandez J . Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2010; 17(2):195-9. PMC: 3034774. DOI: 10.1038/nm.2262. View

Avnir Y, Watson C, Glanville J, Peterson E, Tallarico A, Bennett A . IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity. Sci Rep. 2016; 6:20842. PMC: 4754645. DOI: 10.1038/srep20842. View

Skowronski D, De Serres G, Crowcroft N, Janjua N, Boulianne N, Hottes T . Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med. 2010; 7(4):e1000258. PMC: 2850386. DOI: 10.1371/journal.pmed.1000258. View

Kallewaard N, Corti D, Collins P, Neu U, McAuliffe J, Benjamin E . Structure and Function Analysis of an Antibody Recognizing All Influenza A Subtypes. Cell. 2016; 166(3):596-608. PMC: 4967455. DOI: 10.1016/j.cell.2016.05.073. View

Jegaskanda S, Job E, Kramski M, Laurie K, Isitman G, De Rose R . Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol. 2013; 190(4):1837-48. DOI: 10.4049/jimmunol.1201574. View

DiLillo D, Tan G, Palese P, Ravetch J . Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med. 2014; 20(2):143-51. PMC: 3966466. DOI: 10.1038/nm.3443. View

Harris A, Meyerson J, Matsuoka Y, Kuybeda O, Moran A, Bliss D . Structure and accessibility of HA trimers on intact 2009 H1N1 pandemic influenza virus to stem region-specific neutralizing antibodies. Proc Natl Acad Sci U S A. 2013; 110(12):4592-7. PMC: 3607006. DOI: 10.1073/pnas.1214913110. View

10.

Whittle J, Wheatley A, Wu L, Lingwood D, Kanekiyo M, Ma S . Flow cytometry reveals that H5N1 vaccination elicits cross-reactive stem-directed antibodies from multiple Ig heavy-chain lineages. J Virol. 2014; 88(8):4047-57. PMC: 3993745. DOI: 10.1128/JVI.03422-13. View

11.

Lin S, Liu W, Jan J, Wu S . Glycan masking of hemagglutinin for adenovirus vector and recombinant protein immunizations elicits broadly neutralizing antibodies against H5N1 avian influenza viruses. PLoS One. 2014; 9(3):e92822. PMC: 3966833. DOI: 10.1371/journal.pone.0092822. View

12.

Graves P, SCHULMAN J, Young J, Palese P . Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology. 1983; 126(1):106-16. DOI: 10.1016/0042-6822(83)90465-8. View

13.

Krammer F, Hai R, Yondola M, Tan G, Leyva-Grado V, Ryder A . Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J Virol. 2014; 88(6):3432-42. PMC: 3957929. DOI: 10.1128/JVI.03004-13. View

14.

Lin S, Lin Y, Chong P, Wu S . Broader neutralizing antibodies against H5N1 viruses using prime-boost immunization of hyperglycosylated hemagglutinin DNA and virus-like particles. PLoS One. 2012; 7(6):e39075. PMC: 3374787. DOI: 10.1371/journal.pone.0039075. View

15.

Tran E, Podolsky K, Bartesaghi A, Kuybeda O, Grandinetti G, Wohlbold T . Cryo-electron Microscopy Structures of Chimeric Hemagglutinin Displayed on a Universal Influenza Vaccine Candidate. mBio. 2016; 7(2):e00257. PMC: 4807363. DOI: 10.1128/mBio.00257-16. View

16.

Heinen P, Rijsewijk F, de Boer-Luijtze E, Bianchi A . Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol. 2002; 83(Pt 8):1851-1859. DOI: 10.1099/0022-1317-83-8-1851. View

17.

Xu R, Krause J, McBride R, Paulson J, Crowe Jr J, Wilson I . A recurring motif for antibody recognition of the receptor-binding site of influenza hemagglutinin. Nat Struct Mol Biol. 2013; 20(3):363-70. PMC: 3594569. DOI: 10.1038/nsmb.2500. View

18.

Krammer F, Pica N, Hai R, Margine I, Palese P . Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013; 87(12):6542-50. PMC: 3676110. DOI: 10.1128/JVI.00641-13. View

19.

Steel J, Lowen A, Wang T, Yondola M, Gao Q, Haye K . Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 2010; 1(1). PMC: 2912658. DOI: 10.1128/mBio.00018-10. View

20.

Ekiert D, Bhabha G, Elsliger M, Friesen R, Jongeneelen M, Throsby M . Antibody recognition of a highly conserved influenza virus epitope. Science. 2009; 324(5924):246-51. PMC: 2758658. DOI: 10.1126/science.1171491. View